-
Caged Bioluminescent Probe for the Immunoproteasome
2026-09-01
Loy and Trader present a protocol for synthesizing and applying a cleavable, immunoproteasome-selective activity-based probe that couples a β5i-recognizing peptide with aminoluciferin. The workflow extends immunoproteasome analysis from conventional fluorescence toward plate-reader luminescence, live-cell assays, tissue-mimicking conditions, and potentially future in vivo studies.
-
Polyethylenimine Linear: PEI MW 40,000 Assays
2026-09-01
Build reproducible DNA-delivery workflows for transient gene expression, breast cancer mechanism studies, and recombinant protein production with a serum-compatible PEI formulation. This guide connects practical transfection optimization with the AC008406.3–docetaxel cuproptosis study and provides assay-specific troubleshooting.
-
WM-8014: A Practical KAT6A Inhibitor Workflow
2026-08-31
WM-8014 is a reversible, competitive KAT6A/B inhibitor for connecting acetyl-CoA-site biochemistry with cell-cycle arrest, senescence, and tumor-growth studies. This practical guide translates time-gated CRISPR findings into pharmacological assay designs, dose-timing strategies, and troubleshooting steps for cancer biology research.
-
ZK53: Human Mitochondrial ClpP Activator
2026-08-31
ZK53 enables selective activation of human mitochondrial ClpP, connecting mitochondrial proteostasis to electron transport chain failure, DNA-damage signaling, and ferroptosis sensitivity. This practical guide translates those mechanisms into biochemical, cellular, and tumor-model workflows while separating established product data from assay-development recommendations.
-
Cefepime (BMY-28142) Research Workflows
2026-08-30
Cefepime (BMY-28142) connects reproducible susceptibility testing with plasmid-transfer and central nervous system infection research. This workflow explains how to control preparation, pair phenotype with genotype, and interpret neurotoxicity and resistance signals without confusing exploratory assay results with clinical conclusions.
-
Asunaprevir: Mechanism-to-Readout HCV Analysis
2026-08-29
Asunaprevir and BMS-650032 are examined through a mechanism-to-readout framework that separates protease inhibition from cellular antiviral effects. This article also draws a carefully bounded lesson from HDAC assay design to improve interpretation of HCV RNA replication inhibition studies.
-
Computational Hapten Design for Dual Mushroom Toxin Sensing
2026-08-28
The reference study combines molecular similarity analysis and quantum chemical calculations with antibody engineering to improve balanced recognition of amatoxins and phallotoxins. Its dual-target fluorescent immunochromatographic assay detects both toxin classes in mushroom samples, addressing a major limitation of rapid methods that traditionally measured amatoxins alone.
-
Cefazedone (Refosporen): In Vitro Workflow Guide
2026-08-28
Build more reproducible Cefazedone susceptibility assays with solvent-aware preparation, phenotype-stratified controls, and MIC-to-PK interpretation. This practical guide connects Refosporen’s PBP-directed activity with workflows for respiratory, urinary, skin, and other bacterial research models.
-
Polyethylenimine Linear: PEI MW 40,000 Workflow
2026-08-27
Build reproducible DNA delivery workflows with Polyethylenimine Linear, from HEK-293 transfection to scalable recombinant protein production. This guide combines PEI-specific setup advice with a calcium-phosphate reference study to clarify how DNA concentration, reaction volume, and particle formation affect assay performance.
-
CCK-8 Inhibits IgG1 in LPS-Activated B Cells
2026-08-27
The reference study showed that sulfated cholecystokinin octapeptide suppresses proliferation, IgG1 transcription, and IgG1 production in LPS-activated primary murine B cells. Its receptor-antagonist experiments and transcription-factor analysis identify CCK2R-linked regulation of Blimp1, Pax5, Xbp1, and Bcl6 as a mechanistic framework for studying peptide-mediated control of humoral immunity.
-
MCC950 Sodium: Assay Design for NLRP3 Neuroinflammation
2026-08-26
MCC950 sodium, also known as CRID3 sodium salt, is a selective NLRP3 inflammasome inhibitor with utility beyond conventional macrophage assays. This guide translates evidence from a morphine-tolerance study into practical decisions for measuring inflammasome activity, astrocyte remodeling, and neuroinflammatory phenotypes.
-
WM-8014: Mechanism and KAT6A Inhibition
2026-08-26
WM-8014 is a potent, selective, reversible KAT6A inhibitor that competes with acetyl-CoA at the MYST-domain binding site. Its reported cellular effects include p16INK4A–p19ARF-associated senescence and cell cycle arrest in mouse embryonic fibroblasts, with concentration-dependent activity in a KRAS G12V zebrafish liver model.
-
Aztreonam Workflows for Gram-Negative Research
2026-08-25
Build reproducible Aztreonam assays that connect bacterial susceptibility, resistance-gene transmission, and host-response readouts. This workflow guide combines practical solution handling with orthogonal genomic, progenitor-cell, and hepatic enzyme experiments.
-
TRPV1 Modulation in Metastatic Breast Cancer
2026-08-25
The reference study shows that TRPV1 modulation produces disease-state- and metastasis-dependent immune effects in mice bearing 4T1 breast carcinoma. Its unexpected finding that AMG9810 behaved as an inverse agonist highlights why receptor activity, tumor context, and agonist exposure must be interpreted together before considering TRPV1-directed cancer strategies.
-
Gepotidacin: From Mechanism to Translational Strategy
2026-08-24
Gepotidacin, also known as GSK2140944, offers translational researchers a differentiated way to interrogate bacterial topoisomerase biology, DNA replication inhibition, and antibiotic resistance. This thought-leadership article connects biochemical potency, phenotypic assays, medicinal-chemistry precedent, exposure strategy, and practical material handling into a research roadmap.